Department of Hepatobiliary and Pancreatic Surgery, Henan Tumor Hospital, Zhengzhou, Henan 450008, PR China.
J Exp Clin Cancer Res. 2011 Jan 6;30(1):2. doi: 10.1186/1756-9966-30-2.
Cancer-testis antigens (CTAs) are suitable targets for cancer-specific immunotherapy. The aim of the study is to investigate the expression of CTAs in intrahepatic cholagiocarcinoma (IHCC) and evaluate their potential therapeutic values.
Eighty-nine IHCC patients were retrospectively assessed for their expression of CTAs and HLA Class I by immunohistochemistry using the following antibodies: MA454 recognizing MAGE-A1, 57B recognizing multiple MAGE-A (MAGE-A3/A4), E978 recognizing NY-ESO-1, and EMR8-5 recognizing HLA class I. The clinicopathological and prognostic significance of individual CTA markers and their combination were further evaluated.
The expression rates of MAGE-A1, MAGE-A3/4 and NY-ESO-1 were 29.2%, 27.0% and 22.5%, respectively. The concomitant expression of CTAs and HLA class I antigen was observed in 33.7% of the IHCC tumors. We found that positive MAGE-3/4 expression correlated with larger tumor size (≥ 5 cm), tumor recurrence and poor prognosis. Moreover, we identified 52 cases (58.4%) of IHCC patients with at least one CTA marker expression, and this subgroup displayed a higher frequency of larger tumor size and a shorter survival than the other cases. Furthermore, expression of at least one CTA marker was also an independent prognostic factor in patients with IHCC.
Our data suggest that specific immunotherapy targeted CTAs might be a novel treatment option for IHCC patients.
癌症睾丸抗原（CTAs）是癌症特异性免疫治疗的合适靶标。本研究旨在探讨 CTAs 在肝内胆管癌（IHCC）中的表达，并评估其潜在的治疗价值。
采用 MA454 识别 MAGE-A1、57B 识别多种 MAGE-A（MAGE-A3/A4）、E978 识别 NY-ESO-1 和 EMR8-5 识别 HLA 类 I 等抗体，通过免疫组织化学法对 89 例 IHCC 患者的 CTAs 和 HLA 类 I 表达进行回顾性评估。进一步评估了单个 CTA 标志物及其组合的临床病理和预后意义。
MAGE-A1、MAGE-A3/4 和 NY-ESO-1 的表达率分别为 29.2%、27.0%和 22.5%。33.7%的 IHCC 肿瘤中观察到 CTAs 和 HLA 类 I 抗原的同时表达。我们发现，MAGE-3/4 阳性表达与肿瘤较大（≥5cm）、肿瘤复发和预后不良相关。此外，我们鉴定了 52 例（58.4%）IHCC 患者至少有一种 CTA 标志物表达，与其他病例相比，该亚组的肿瘤较大和生存时间较短的频率更高。此外，IHCC 患者中至少有一种 CTA 标志物的表达也是独立的预后因素。
我们的数据表明，针对特定 CTAs 的免疫治疗可能是 IHCC 患者的一种新的治疗选择。
Zotero 插件
